论文部分内容阅读
目的:观察过氧化物酶体增殖物激活受体γ(PPARγ)配体吡格列酮对糖尿病大鼠血清基质金属蛋白酶9(MMP-9)浓度和外周血单核细胞中MMP-9表达的影响。方法:40只Wistar大鼠随机分为5组,即对照组、糖尿病组和不同剂量5、10、20mg/(kg.d)吡格列酮治疗组,每组8只。给糖尿病组和3个吡格列酮治疗组大鼠腹腔注射链脲霉素制作糖尿病大鼠模型后,各吡格列酮治疗组以不同剂量的吡格列酮灌胃:5、10、20mg/(kg.d),共28d;对照组和糖尿病组以等量生理盐水灌胃。比较治疗前、后的血清MMP-9浓度的变化。分离大鼠外周血单核细胞,用RT-PCR和Westernblot检测MMP-9表达的变化。结果:与对照组比较,吡格列酮降低血清MMP-9的浓度(P<0.05),降低外周血单核细胞中MMP-9的表达。结论:吡格列酮可以降低糖尿病大鼠血清MMP-9浓度及外周血单核细胞中MMP-9的表达,提示其在降糖之外还具有心血管保护作用。
OBJECTIVE: To observe the effect of pioglitazone, a ligand of peroxisome proliferator-activated receptor γ (PPARγ), on the serum levels of matrix metalloproteinase 9 (MMP-9) and the expression of MMP-9 in peripheral blood mononuclear cells in diabetic rats. Methods: Forty Wistar rats were randomly divided into five groups: control group, diabetic group and different doses of 5, 10, 20 mg / (kg.d) pioglitazone treatment group, with 8 rats in each group. To diabetic group and three pioglitazone-treated rats intraperitoneal injection of streptozotocin to make diabetic rat model, each pioglitazone treatment group with different doses of pioglitazone gavage: 5,10,20 mg / (kg.d), a total of 28d The control group and diabetic group were given normal saline. The changes of serum MMP-9 concentration before and after treatment were compared. Peripheral blood mononuclear cells were isolated and the changes of MMP-9 expression were detected by RT-PCR and Western blotting. Results: Compared with the control group, pioglitazone reduced the serum MMP-9 concentration (P <0.05) and decreased the expression of MMP-9 in peripheral blood mononuclear cells. Conclusion: Pioglitazone can reduce the concentration of serum MMP-9 in diabetic rats and the expression of MMP-9 in peripheral blood mononuclear cells, suggesting that it may have cardiovascular protective effects in addition to hypoglycemic agents.